Please login to the form below

Not currently logged in
Email:
Password:

Verona names David Ebsworth as non-executive chairman

He joins from Vifor Pharma
Verona names David Ebsworth as non-executive chairman

Verona Pharma has appointed Dr David Ebsworth as its non-executive chairman of the board of directors.

Ebsworth's role will be effective from December 1 when he will take over from Prof Clive Page, who has held the position since founding the company in 2006.

Ebsworth (pictured) is an experienced pharma executive who has worked at board and senior management level at a number of international companies. He most recently served as CEO at Vifor Pharma and was also named CEO of Galenica in 2011, continuing to be an adviser for both firms.

His career in the pharma industry spans over 35 years, including a 19-year stint at Bayer where he worked up through the company from product manager to general manager of the global pharma division.

Commenting on his appointment, Ebsworth said: “I am looking forward to working closely with Verona Pharma's board and management to guide the company towards success. I shall use my background and experience in both international pharma and biotech to support this innovative company within the hugely rewarding respiratory space.”

Dr Jan-Anders Karlsson, CEO of Verona Pharma, said: “We thank Clive for all his achievements as we welcome David to the board. David' significant expertise in the pharma industry strongly supports Verona Pharma's focus on high value commercial opportunities and future growth.”

24th November 2014

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Value is in the eye of the customer. Co-creation is a bridge to value.
We conducted 16 hours of qualitative interviews with HCPs and Senior Pharma industry leaders in the UK, supported with in-depth industry scanning. Our interviews reveal important insights about the tensions...
Partnering with Patients and Caregivers in Clinical Research
...
Practical advice for Early Scientific Advice (ESA) in HTA submissions
A step-by step guide on the benefits, processes, and key considerations involved in the Healthcare Technology Assessment (HTA) Early Scientific Advice (ESA) consultation as part of planning the holistic evidence...